دورية أكاديمية
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin's lymphoma:results from the randomized international GHSG HD18 trial
| العنوان: | Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin's lymphoma:results from the randomized international GHSG HD18 trial |
|---|---|
| المؤلفون: | Ferdinandus, J., Müller, H., Damaschin, C., Jacob, A. S., Meissner, J., Krasniqi, F., Mey, U., Schöndube, D., Thiemer, J., Mathas, S., Zijlstra, J., Greil, R., Feuring-Buske, M., Markova, J., Rüffer, J. U., Kobe, C., Eich, H. T., Baues, C., Fuchs, M., Borchmann, P., Behringer, K. |
| المصدر: | Ferdinandus , J , Müller , H , Damaschin , C , Jacob , A S , Meissner , J , Krasniqi , F , Mey , U , Schöndube , D , Thiemer , J , Mathas , S , Zijlstra , J , Greil , R , Feuring-Buske , M , Markova , J , Rüffer , J U , Kobe , C , Eich , H T , Baues , C , Fuchs , M , Borchmann , P & Behringer , K 2024 , ' Impact of individualized treatment on recovery from fatigue and return .... |
| سنة النشر: | 2024 |
| الوصف: | Background: Persisting cancer-related fatigue impairs health-related quality of life (HRQoL) and social reintegration in patients with Hodgkin's lymphoma (HL). The GHSG HD18 trial established treatment de-escalation for advanced-stage HL guided by positron emission tomography after two cycles (PET-2) as new standard. Here, we investigate the impact of treatment de-escalation on long-term HRQoL, time to recovery from fatigue (TTR-F), and time to return to work (TTR-W). Patients and methods: Patients received European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and life situation questionnaires at baseline, interim, end of treatment, and yearly follow-up. TTR-F was defined as time from the end of chemotherapy until the first fatigue score <30. TTR-W was analyzed in previously working or studying patients and measured from the end of treatment until the first documented work or education. We compared duration of treatment on TTR-F and TTR-W using Cox proportional hazards regression adjusted for confounding variables. Results: HRQoL questionnaires at baseline were available in 1632 (83.9%) of all randomized patients. Overall, higher baseline fatigue and age were significantly associated with longer TTR-F and TTR-W and male sex with shorter TTR-W. Treatment reduction from eight to four chemotherapy cycles led to a significantly shorter TTR-F [hazard ratio (HR) 1.41, P = 0.008] and descriptively shorter TTR-W (HR 1.24, P = 0.084) in PET-2-negative patients. Reduction from six to four cycles led to non-significant but plausible intermediate accelerations. The addition of rituximab caused significantly slower TTR-F (HR 0.70, P = 0.0163) and TTR-W (HR 0.64, P = 0.0017) in PET-2-positive patients. HRQoL at baseline and age were the main determinants of 2-year HRQoL. Conclusions: Individualized first-line treatment in patients with advanced-stage HL considerably shortens TTR-F and TTR-W in PET-2-negative patients. Our results support the use of response-adapted ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://research.vumc.nl/en/publications/ee750414-f47a-46f7-95da-b68b321b8618Test |
| DOI: | 10.1016/j.annonc.2023.11.014 |
| الإتاحة: | https://doi.org/10.1016/j.annonc.2023.11.014Test https://research.vumc.nl/en/publications/ee750414-f47a-46f7-95da-b68b321b8618Test http://www.scopus.com/inward/record.url?scp=85183544403&partnerID=8YFLogxKTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.48459832 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.annonc.2023.11.014 |
|---|